Business Context and Reporting Period
Company: Entrada Therapeutics, Inc. (TRDA)
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2026
Reporting Period: Financial data reflects the period ended December 31, 2025. The filing primarily addresses unaudited cash position estimates and clinical development updates.
Key Financial Metrics
Liquidity and Cash Position:
- Cash, Cash Equivalents, and Marketable Securities: Approximately $296 million as of December 31, 2025.
- Runway: Management estimates cash resources are sufficient into the third quarter of 2027.
- Revenue, Profit, Margins, Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels. The financial information is described as unaudited and preliminary, intended to supplement but not replace the full annual report.
Material Changes and Clinical Progress
The filing details significant advancements in the Company's RNA-based therapeutic portfolio for neuromuscular and ocular diseases:
- ENTR-601-44 (Duchenne Muscular Dystrophy - Exon 44): Completed dosing of Cohort 1 in the global Phase 1/2 multiple ascending dose (MAD) study and transitioned to the open-label Phase 2 portion. Received Rare Pediatric Disease Designation from the FDA in December 2025.
- ENTR-601-50 (Duchenne Muscular Dystrophy - Exon 50): Received regulatory authorization from the U.K. MHRA and Research Ethics Committee to initiate a Phase 1/2 MAD study.
- ENTR-801 (Ocular Diseases): Selected as the first clinical candidate for the treatment of Usher syndrome type 2A.
- Partnership: Collaboration with Vertex Pharmaceuticals on VX-670 for myotonic dystrophy type 1 is ongoing.
Guidance, Outlook, and Risks
Future Milestones and Timelines:
- Data Readouts: ELEVATE-44-201 (Cohort 1) data expected in Q2 2026; ELEVATE-45-201 (Cohort 1) data expected in mid-2026.
- Study Initiation: Global Phase 1/2 MAD study for ENTR-601-50 expected to initiate by the end of 2026. ELEVATE-44-102 study in the U.S. expected in the first half of 2026.
- Regulatory Filings: Global regulatory applications for ENTR-601-51 expected in 2026. A second ocular clinical candidate nomination is expected in 2026.
- Vertex Collaboration: Enrollment and dosing of the MAD portion of the VX-670 study expected to complete in the first half of 2026.
- Financial figures are unaudited and preliminary; final audited statements may differ.
- Forward-looking statements regarding clinical timelines, regulatory approvals, and cash sufficiency are subject to risks and uncertainties, including factors beyond the Company's control.
- Investors are directed to the "Risk Factors" in the Form 10-Q for the quarter ended September 30, 2025, for a comprehensive list of risks.
Investor Verification Checklist
- Cash Runway: Verify the $296 million cash balance and the sufficiency of funds through Q3 2027 against upcoming burn rates and clinical trial costs.
- Clinical Timelines: Monitor the Q2 2026 data readout for ENTR-601-44 and the initiation of the ENTR-601-50 study by year-end 2026.
- Regulatory Status: Confirm the status of the FDA Rare Pediatric Disease Designation for ENTR-601-44 and the U.K. authorization for ENTR-601-50.
- Audited Financials: Await the final audited consolidated financial statements for the year ended December 31, 2025, to confirm revenue, expenses, and debt positions.
- Pipeline Expansion: Track the nomination of the second ocular clinical candidate in 2026.